Association between the number of cycles of neoadjuvant chemoimmunotherapy and treatment outcomes in stage II-IIIB non-small cell lung cancer
Neoadjuvant chemoimmunotherapy has improved outcomes in resectable non-small cell lung cancer (NSCLC), yet the optimal number of treatment cycles remains uncertain. This study evaluated the association between the number of treatment cycles and treatment outcomes in patients with stage II-IIIB NSCLC and expl...